首页> 美国卫生研究院文献>The British Journal of Ophthalmology >α/β− and γ/δ TCR+ lymphocyte infiltration in necrotising choroidal melanomas
【2h】

α/β− and γ/δ TCR+ lymphocyte infiltration in necrotising choroidal melanomas

机译:坏死性脉络膜黑色素瘤中的α/β-和γ/δTCR +淋巴细胞浸润

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM—To detect specific tumour infiltrating T cells (TIL) carrying antigen specific MHC-I restricted receptor genes on necrotising and non-necrotising malignant melanomas and to correlate the findings with clinical data.
METHODS—α/β− and γ/δ− TIL were determined by immunohistochemical staining in melanomas of patients with known follow up of more than 10 years. An antigen retrieval method was used to determine variable genes δ1 and γ1 on TCR+ cells by an anti-TCR Vδ1 and anti-CrγM1, and of Vα and Vβ TCR+ by an anti-pan-TCR+ α/β antibody.
RESULTS—Intratumoral TIL were present in 86 of 113 (76.1%) necrotising melanomas (NMM) v 21 of 100 (21%) in non-necrotising melanomas (MM); of these, Vα/β− TCR+ cells were present in 52 of 74 (70.3%) TIL harbouring NMM v four of 21 (19%) MM; Vγ1 in 29 of 74 (39.2%) NMM v two of 21 (10%) MM; and Vδ1 in 39 of 74 (52.7%) NMM v three of 21 (14%) MM. Extratumoral lymphocytic infiltration was seen in 86 (76.1%) NMM including Vα/β TCR+ cells in 10 (11.6%) cases, v five (5%) MM cases with no Vα/β TCR+ cells detected. Vγ1 and Vδ1 TCR+ cells were not found in extratumoral infiltrates.
CONCLUSIONS—In NMM, the median survival was 69.3 (range 6-237) months, 19 of 74 patients (25.7%) survived 5 years, and mortality was associated with advanced stage (p<0.001), patient age (p<0.023), and extent of necrosis (p<0.048). Survival was increased with evidence of Vγ1 and Vδ1 TCR+ cells (p<0.026).

机译:目的:检测携带坏死性和非坏死性恶性黑色素瘤的抗原特异性MHC-I限制性受体基因的特定肿瘤浸润性T细胞(TIL),并将其发现与临床数据相关联。
方法-α/β-和γ /δ-TIL是通过免疫组织化学染色在已知随访时间超过10年的患者的黑色素瘤中测定的。用抗原回收法通过抗TCRVδ1和抗CrγM1来确定TCR + 细胞上的可变基因δ1和γ1,并通过VTL TCR + 来确定Vα和VβTCR + 结果:在113例(76.1%)坏死性黑色素瘤(NMM)中有86例存在瘤内TIL,而100例(21%)中有21例存在瘤内TIL。在非坏死性黑色素瘤(MM)中;其中74个(70.3%)的TIL中存在Vα/β-TCR + 细胞,其中NMM占21个(19%)MM中的四个; 74个(39.2%)NMM中的29个中的Vγ1对21个(10%)MM中的两个;和74个(52.7%)NMM中的39个中的Vδ1与21个(14%)MM中的三个相对应。包括Vα/βTCR + 细胞在内的86个(76.1%)NMM中可见肿瘤外淋巴细胞浸润,其中10个(11.6%)病例中有五例(5%)MM无Vα/βTCR + 个细胞。在肿瘤外浸润中未发现Vγ1和Vδ1TCR + 细胞。
结论—在NMM中,中位生存期为69.3(6-237)个月,在74位患者中有19位(25.7%)存活5年,死亡率与晚期(p <0.001),患者年龄(p <0.023)和坏死程度(p <0.048)相关。有Vγ1和Vδ1TCR + 细胞的证据可提高存活率(p <0.026)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号